PGLS _ 6PGL antigen
- Known as:
- PGLS _ 6PGL antigenic
- Catalog number:
- 'H00025796-P01-25
- Product Quantity:
- 25
- Category:
- -
- Supplier:
- ACR
- Gene target:
- PGLS _ 6PGL antigen
Related genes to: PGLS _ 6PGL antigen
- Gene:
- PGLS NIH gene
- Name:
- 6-phosphogluconolactonase
- Previous symbol:
- -
- Synonyms:
- 6PGL
- Chromosome:
- 19p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2000-01-20
- Date modifiied:
- 2015-08-25
Related products to: PGLS _ 6PGL antigen
'F 4_80 Antigen (mouse) Host Rat'F 4_80 Antigen (mouse) Host Rat(Anti_Tg)Thyroglobulin Antigen(Des-Asp187)-Melanocyte Protein PMEL 17 (185-193) (human, bovine, mouse)
(Des-Asp187)-ME20M_ME20S (185-193) (human, bovine, mouse), (Des-Asp187)-Melanocyte Lineage-Specific Antigen GP100 (185-193) (hu(Des-Asp187,Met186)-Melanocyte Protein PMEL 17 (185-193) (human, bovine, mouse)
(Des-Asp187,Met186)-Melanoma-Associated ME20 Antigen (185-193) (human, bovine, mouse), (Des-Asp187,Met186)-95 kDa Melano(Des_Asp187,Met186)_Melanocyte Protein PMEL 17 (185_193) (human, bovine, mouse) Salt Trifluoroacetate Binding _ Synonym (Des_Asp187,Met186)_Melanoma_Associated ME20 Antigen (185_193) (human, bovine(Des_Asp187,Met186)_Melanocyte Protein PMEL 17 (185_193) (human, bovine, mouse) Salt Trifluoroacetate Binding _ Synonym (Des_Asp187,Met186)_Melanoma_Associated ME20 Antigen (185_193) (human, bovine(Des_Asp187,Met186)_Melanocyte Protein PMEL 17 (185_193) (human, bovine, mouse) Salt Trifluoroacetate Binding _ Synonym (Des_Asp187,Met186)_Melanoma_Associated ME20 Antigen (185_193) (human, bovine(Des_Asp187,Met186)_Melanocyte Protein PMEL 17 (185_193) (human, bovine, mouse) Salt Trifluoroacetate Binding _ Synonym (Des_Asp187,Met186)_Melanoma_Associated ME20 Antigen (185_193) (human, bovine(Draxin) C1ORf187, Antigen blocking peptide(Val438)-Tyrosinase (432-444) (human)
(Val438)-LB24-AB (432-444) (human), (Val438)-Monophenol Monooxygenase (432-444) (human), (Val438)-SK29-AB (432-444) (human), (Val438)-Tumor Rejection Antigen AB (0x19 Antigen0x2 Antigen1,25-dihydroxyvitamin D3 Competitive ELISA, Coated with Antigen105 kDa islet cell antigen,BEM-3,Brain-enriched membrane-associated protein tyrosine phosphatase,ICA105,PTP IA-2,PTPLP,Ptprn,Rat,Rattus norvegicus,Receptor-type tyrosine-protein phosphatase-like N,R-P Related articles to: PGLS _ 6PGL antigen
- This exploratory pilot study, employing a single-center and cross-sectional design, aimed to characterize urinary protein alterations associated with pediatric metabolic-associated fatty liver disease (MAFLD) and to identify preliminary candidate proteins associated with MAFLD status within a cohort of children with obesity. - Source: PubMed
Publication date: 2026/06/23
Zhang XiaohuiZhu ZhongyiZhou ZhaoxinLiu ChangDu LinaGuo ZiyunPu GuoweiHe QiangYang Yan - Paraganglioma (PGL) is a rare non-epithelial neuroendocrine neoplasm that can occur in multiple locations within the body. Most PGLs grow slowly and are benign, but some can metastasize to distant sites. Reports of brain metastatic PGL are relatively rare, particularly those with comprehensive case histories. - Source: PubMed
Publication date: 2026/06/18
Zhang HongweiQiao XiaolongWang ZixuanLi QinCheng Chuandong - Pheochromocytomas and paragangliomas, collectively known as paragangliomas (PGLs), are rare neuroendocrine tumors originating from chromaffin cells. Surgical resection is the treatment of choice, with preoperative α-adrenoceptor blockade being consistently used prior to any surgical intervention; however, this approach has recently been challenged. This comprehensive systematic review of the literature was conducted across PubMed, Embase, and the Cochrane Library up to December 2025 to address the necessity and potential indications of α-adrenoceptor blockade in the pre-, peri-, and postoperative phase of PGL management. Papers were categorized into guidelines/consensus, meta-analyses, and clinical studies. All international guidelines uniformly recommend preoperative α-adrenoceptor blockade for functional PGLs, albeit there is no substantial evidence to support abandoning this long-standing practice. Therefore, both for medicolegal considerations and for alignment with current clinical practice, the recommendation for preoperative α-adrenoceptor blockade is still widely utilized. However, recent meta-analyses and patient cohort studies indicate no significant benefits in terms of mortality, intraoperative, or postoperative outcomes using such agents in selective patient populations. The paucity of randomized controlled trials and the recent progress in clinical practice and surgical/anesthetic techniques underscore the need for a reevaluation of the routine use of α-adrenoceptor blockade during PGL surgical resections to resolve this issue. - Source: PubMed
Publication date: 2026/06/08
Angelousi AnnaMemi EleniZografos George NChatzellis EleftheriosKassi EvaKaltsas Gregory - The prognostic importance of tumor location in pheochromocytomas and paragangliomas (PPGLs) remains controversial. This study aimed to assess whether anatomic site independently influences survival in PPGLs. - Source: PubMed
Wu KanBai HexiangLiu XuZhu YuchunLi XiangLiu Zhihong - Middle ear paragangliomas (ME-PGLs) are rare non-epithelial neuroendocrine neoplasms and the most common neoplasms of the middle ear. Tympanic paragangliomas (Ty-PGLs), a subset of ME-PGLs, are often biochemically non-functional, although prior studies have reported expression of cholinergic and, less frequently, catecholaminergic markers. The expression of functional biomarkers and somatostatin receptor type 2 A (SSTR2A) remains poorly defined in Ty-PGLs. We analyzed three surgically resected Ty-PGLs from adult patients without hyperadrenergic symptoms using immunohistochemistry. All tumors exhibited strong, diffuse tyrosine hydroxylase expression; dopamine β-hydroxylase was negative in all cases, while choline acetyltransferase was focally positive in only one case. All Ty-PGLs showed moderate membranous SSTR2A expression. These findings indicate that a catecholaminergic immunophenotype may be relatively common in Ty-PGLs, challenging the traditional distinction between sympathetic and parasympathetic paragangliomas. Further studies are needed to clarify the clinical significance of these features and the physiological role of tympanic paraganglia. - Source: PubMed
Publication date: 2026/05/13
Vanoli AlessandroCarlotto ElenaMinetto MarcoGrillo FedericaNeri GiuseppeLenti Marco VincenzoDi Sabatino AntonioViglio AlessandraPaulli MarcoLa Rosa StefanoPasini AlessandraMarchiori DeborahBenazzo MarcoCanzi Pietro